AL
ALMS.US Alumis Inc
- Market cap
- USD 725M
- P/E
- -
- P/B
- 1.75x
- ROE
- -116.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ALMS.US undervalued?
Graham numberThe Graham number of Alumis Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Alumis Inc fundamental analysis
No fundamental analysis for Alumis Inc yet.
Alumis Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Alumis Inc
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab…
Full company profileAlumis Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Alumis Inc annual financial statements
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 24.1M | 7.08M |
| Gross Profit | -250K | -1.28M | -3.15M | 20.6M | 5.92M |
| Operating Income | -114M | -158M | -301M | -427M | -462M |
| EBITDA | -112M | -154M | -291M | -248M | -445M |
| Net Income | -112M | -155M | -294M | -243M | -440M |
| EPS | -15 | -2.99 | -10 | -0.29 | -3.40 |
| Balance Sheet | |||||
| Total Assets | 108M | 89.6M | 341M | 412M | 489M |
| Total Liabilities | 303M | 429M | 80.9M | 111M | 110M |
| Shareholders' Equity | -195M | -339M | 260M | 301M | 378M |
| Cash & Short-term Investments | 92.9M | 49.0M | 288M | 309M | 431M |
| Total Debt | 1.78M | 32.6M | 30.7M | 36.9M | 35.3M |
| Cash Flow | |||||
| Operating Cash Flow | -108M | -130M | -255M | -370M | -331M |
| Capital Expenditure | 2.41M | 4.50M | 1.73M | 653K | 1.15M |
| Free Cash Flow | -110M | -134M | -257M | -370M | -332M |
| Ratios | |||||
| ROE | - | - | -113.1% | -80.8% | -116.3% |
| ROA | -103.5% | -173.0% | -86.3% | -59.1% | -90.1% |
| Net Profit Margin | - | - | - | -1,011.7% | -6,217.6% |
| Debt to Equity | - | - | 0.12x | 0.12x | 0.09x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Alumis Inc dividends
Alumis Inc has not paid dividends in the last 4 fiscal years.
Who owns Alumis Inc
- Insiders 0.52%
- Institutions 88.10%
- Public & others 11.38%
- Shares outstanding 129M
- Free float 91.6M
Top funds holding ALMS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 3.15M | 2.43% | +0.03% | Sep 2026 |
| HBM Healthcare Investments AG Ord | 2.19M | 1.69% | +38.68% | Sep 2026 |
| iShares Russell 2000 ETF | 1.98M | 1.53% | 0.00% | Oct 2026 |
| Fidelity Stock Selector Small Cap | 1.17M | 0.90% | +6.07% | Aug 2026 |
| Fidelity Small Cap Growth | 1.10M | 0.85% | 0.00% | Aug 2026 |
| Fidelity Select Health Care | 972K | 0.75% | +3.36% | Aug 2026 |
| State Street® SPDR® S&P® PhrmctlsETF | 944K | 0.73% | +2.88% | Oct 2026 |
| Fidelity Small Cap Index | 865K | 0.67% | +0.16% | Aug 2026 |
| iShares Biotechnology ETF | 751K | 0.58% | -0.19% | Oct 2026 |
| iShares Russell 2000 Growth ETF | 745K | 0.58% | -0.38% | Oct 2026 |
| Fidelity Select Biotechnology | 597K | 0.46% | 0.00% | Aug 2026 |
| Fidelity Series Small Cap Opps | 590K | 0.46% | -6.81% | Aug 2026 |
| T. Rowe Price New Horizons | 573K | 0.44% | -54.05% | Sep 2026 |
| Fidelity Small Cap Growth K6 | 572K | 0.44% | 0.00% | Aug 2026 |
| Janus Henderson Hrzn Biotec E2 USD | 525K | 0.41% | +17.21% | Jun 2026 |
| Schwab US Small-Cap ETF™ | 481K | 0.37% | +0.24% | Oct 2026 |
| Vanguard Russell 2000 ETF | 458K | 0.35% | +1.01% | Sep 2026 |
| Pictet-Biotech P USD | 439K | 0.34% | 0.00% | Jul 2026 |
| MEDICAL BioHealth EUR Acc | 435K | 0.34% | -12.11% | Aug 2026 |
| Fidelity Extended Market Index | 411K | 0.32% | -0.84% | Sep 2026 |
Top institutions holding ALMS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 8.22M | 6.35% | +14.60% | Jun 2026 |
| FMR Inc | 6.77M | 5.23% | +595.14% | Jun 2026 |
| Deep Track Capital, LP | 6.35M | 4.90% | -6.26% | Jun 2026 |
| Samsara BioCapital, LLC | 6.35M | 4.90% | 0.00% | Jun 2026 |
| Foresite Capital Management V, LLC | 5.90M | 4.56% | 0.00% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 5.20M | 4.02% | +58.21% | Jun 2026 |
| venBio Partners LLC | 4.53M | 3.50% | 0.00% | Jun 2026 |
| Foresite Capital Management VI LLC | 4.25M | 3.28% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 4.22M | 3.26% | +4.55% | Jun 2026 |
| Nextech Invest, Ltd. | 3.54M | 2.74% | 0.00% | Jun 2026 |
| Cormorant Asset Management, LLC | 3.29M | 2.54% | -16.80% | Jun 2026 |
| Saturn V Capital Management LLC | 2.92M | 2.25% | -8.95% | Jun 2026 |
| Octagon Capital Advisors LP | 2.83M | 2.19% | 0.00% | Jun 2026 |
| Jupiter Topco LLC | 2.36M | 1.82% | 0.00% | Jun 2026 |
| State Street Corp | 2.19M | 1.69% | +21.39% | Jun 2026 |
| Geode Capital Management, LLC | 2.17M | 1.68% | +13.04% | Jun 2026 |
| MPM Oncology Impact Management LP | 2.02M | 1.56% | -15.40% | Jun 2026 |
| Baker Bros Advisors LP | 2.01M | 1.55% | 0.00% | Jun 2026 |
| SR ONE CAPITAL MANAGEMENT, LP | 1.96M | 1.51% | 0.00% | Jun 2026 |
| Amvescap Plc. | 1.17M | 0.91% | -22.36% | Jun 2026 |
Alumis Inc company profile
- Company name
- Alumis Inc
- Ticker
- ALMS.US
- Exchange
- USA Stocks
- Listed since
- Jun 28, 2024
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 237
- Fiscal year end
- December
- Address
- 280 East Grand Avenue, South San Francisco, CA, United States, 94080
- Phone
- 650 231 6625
- Website
- alumis.com
About Alumis Inc
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Alumis Inc management
10- Mr. Martin Babler Ph.D.President, CEO & Chairman · born 1965
- Dr. David M. Goldstein Ph.D.Chief Scientific Officer · born 1966
- Dr. Jorn Drappa M.D., Ph.D.Chief Medical Officer & Head of Research and Development · born 1965
- Mr. John R. Schroer C.F.A.Chief Financial Officer · born 1965
- Ms. Sanam Pangali J.D.Chief Legal Officer & Corporate Secretary · born 1984
- Mr. Roy C. Hardiman J.D.Chief Business & Strategy Officer · born 1960
- Ms. Claire Langrish Ph.D.Senior VP & Head of Immunology and Translational Science
- Mr. Philip Nunn Ph.D.Senior VP of Pharmacology & Project Team Leader
- Mr. Mark BradleyChief Development Officer · born 1966
- Mr. Kolbot By Ph.D.Senior VP & Head of Technical Operations